Saturday, July 11, 2026

pharma · Cervical Cancer · Non-small Cell Lung Cancer

Sichuan Baili Pharmaceutical

Sichuan Baili Pharmaceutical clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
4
Drugs
0
Patents
0
Intelligence · Clinical Programs

Sichuan Baili Pharmaceutical projects

3 ClinicalTrials.gov programs sponsored by Sichuan Baili Pharmaceutical.

Sichuan Baili Pharmaceutical has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. BL-B01D1

    Sichuan Baili Pharmaceutical Co.,

    Cervical Cancer

    phase 2 small molecule active

    1 trial
  2. BL-B01D1

    Sichuan Baili Pharmaceutical Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  3. SI-B001

    Sichuan Baili Pharmaceutical Co.,

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Sichuan Baili Pharmaceutical have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.